Gounder, M. M., Somaiah, N., Attia, S., Chawla, S. P., Villalobos, V. M., Chmielowski, B., … Abdul Razak, A. R. (2018). Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. In Journal of Clinical Oncology (Vol. 36, pp. 11512–11512). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.11512

Gounder, Mrinal M., Neeta Somaiah, Steven Attia, Sant P. Chawla, Victor Manuel Villalobos, Bartosz Chmielowski, Melissa Amber Burgess, et al. “Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.” In Journal of Clinical Oncology, 36:11512–11512. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.11512.

Gounder MM, Somaiah N, Attia S, Chawla SP, Villalobos VM, Chmielowski B, et al. Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 11512–11512.

Gounder, Mrinal M., et al. “Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 11512–11512. Crossref, doi:10.1200/jco.2018.36.15_suppl.11512.

Gounder MM, Somaiah N, Attia S, Chawla SP, Villalobos VM, Chmielowski B, Burgess MA, Schwartz GK, Riedel RF, von Mehren M, Wagner AJ, Choy E, Verma S, Mudenda B, Sadanowicz M, Shah JJ, Li L, Shacham S, Kauffman MG, Abdul Razak AR. Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 11512–11512.